Expanding on previous work, a novel SLAMF7-promoter driven oncolytic Ad5 (Ad[CE1A]), specifically targeting SLAMF7 expressing cells, was generated and its efficacy against myeloma (cell lines, patient-derived cells and murine models) was assessed. This evidence concerns the gene SLAMF7 and plasma cell myeloma.